Sources

Reviewed 2026-08-17 against the primary publications. Clinical review of this book remains PENDING. These are sources, not a reading list of AI summaries.

1. Stevens J, et al. The definition of weight maintenance. Int J Obes. 2006. PMID 16302013.
2. Wilding JPH, et al. STEP 1 trial extension. Diabetes Obes Metab. 2022. PMID 35441470.
3. Rubino D, et al. STEP 4. JAMA. 2021. PMID 33755728.
4. Garvey WT, et al. STEP 5. Nat Med. 2022. PMID 36216945.
5. Ryan DH, et al. SELECT weight analysis. Nat Med. 2024. PMID 38740993.
6. Aronne LJ, et al. SURMOUNT-4. JAMA. 2024. PMID 38078870.
7. Horn DB, et al. SURMOUNT-MAINTAIN. Lancet. 2026. PMID 42119587.
8. Sumithran P, et al. Hormonal adaptations after weight loss. N Engl J Med. 2011. PMID 22029981.
9. Rosenbaum M, et al. Persistence of adaptive thermogenesis. Am J Clin Nutr. 2008. PMID 18842775.
10. Jensen SBK, et al. Exercise, liraglutide, or both, then one year without treatment. eClinicalMedicine. 2024. PMC10965408.
11. Rodriguez PJ, et al. GLP-1 discontinuation and reinitiation. JAMA Netw Open. 2025. Article 2829779.
12. Obesity Canada adult clinical practice guideline. PMC12350384.
13. American Diabetes Association Standards of Care. PMC11635032.
14. VA/DoD Clinical Practice Guideline for the Management of Adult Overweight and Obesity, 2025. Guideline PDF.
15. World Health Organization. Guideline on GLP-1 medicines in treating obesity, 1 Dec 2025. WHO news.
16. Lean-mass and resistance-training evidence during weight loss. PMID 40909191.
17. Higher-protein patterns and weight-loss maintenance. PMID 31443231.
18. Wu H, et al. Review of weight regain after incretin-based therapy. PMID 41938838.
19. BMJ 2026 analysis of weight-management medicines after withdrawal. bmj-2025-085304.
20. Additional incretin maintenance review. PMID 41399474.
21. SURMOUNT cardiometabolic outcomes context. PMID 41284285.
22. Real-world post-discontinuation trajectories. PMID 41713959.